Applying Performance Measures Through a Chronic Disease Model to Optimize Treatment of Bipolar Mania
neuroscienceCME Live and On Demand
Premiere Date: Wednesday, February 17, 2010This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, August 17, 2011
Note: Credit Is No Longer Available
 | Roger S. McIntyre, MD, FRCPC (Moderator) University of Toronto University Health Network Toronto, ON Chairman and Executive Director, Brain and Cognition, Depression and Bipolar Support Alliance (DBSA) Chicago, IL Clinical Professor, Department of Psychiatry and Neurosciences University of California School of Medicine Riverside, CA |
 | Leslie Citrome, MD, MPH Adjunct Professor of Psychiatry & Behavioral Sciences New York Medical College Valhalla, NY |
 | Gary S. Sachs, MD Co-Director, Bipolar Clinic and Research Program Massachusetts General Hospital Founder, Concordant Rater Systems Associate Professor of Psychiatry Harvard Medical School Boston, MA |
| Amit Anand, MD (Content/Peer Reviewer) Professor of Psychiatry and Radiology Indiana University Bloomington, IN |
Bipolar disorder is a complicated and severe mental disorder associated with a recurrent or chronic course, insufficient
clinical response, and psychosocial impairment in a substantial number of patients. Bipolar disorder presents with
pleomorphic signs and symptoms varying from depression to hypomania, full-blown mania, mixed states, and
psychosis. Due to the complexity of the disease, the assessment of patients with bipolar disorder poses a difficult
challenge to clinicians. Upon diagnosis, it is paramount to understand the different classifications of medications
available for treatment to ensure the patient is getting the best care possible based on evidence and treatment
guidelines considering safety and long-term efficacy. In this neuroscienceCME Live and On Demand activity, the faculty
will apply a chronic disease model to the diagnosis and management of bipolar mania focusing on achievement of
performance measure-based benchmarks that can improve patient outcomes.
Bauer MS, et al. Enhancing multiyear guideline concordance for bipolar disorder through collaborative care. Am J Psychiatry 2009;166:1244-1250.
Kupfer DJ, et al. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry 2002;63:120–125.
To improve utilization of measurement tools within a chronic disease model in patients with bipolar mania.
At the end of this CE activity, participants should be able to:
- Identify strategies for detecting mania or hypomania in patients presenting with depressive symptoms, in accordance with validated guidelines and performance measures.
- Compare evidence-based treatment strategies that can be implemented early in the course of bipolar disorder to address mania symptoms.
- Recognize the elements of a chronic care model that should be considered when developing a long-term management plan in patients with bipolar mania.
Indiana University School of Medicine and CME Outfitters, LLC, gratefully acknowledge educational grants from Bristol- Myers Squibb Company and Otsuka America Pharmaceutical, Inc., and from Pfizer Inc. in support of this CE activity.
Physicians, physician assistants, nurse practitioners, nurses, and other healthcare professionals interested in mental health.
CME Credit (Physicians):
Indiana University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Indiana University School of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
(Live activity) This continuing nursing
education activity was approved by the New York State
Nurses Association, an accredited approver by the American
Nurses Credentialing Center’s Commission on Accreditation.
It has been assigned approval code 7ZMR8E-10. 1.0 contact
hours will be awarded upon successful completion.
(Archive activity) This continuing nursing education activity
was approved by the New York State Nurses Association, an
accredited approver by the American Nurses Credentialing
Center’s Commission on Accreditation.
It has been assigned approval code 7ZMRM6-10. 1.0 contact
hours will be awarded upon successful completion.
This continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC.
Disclosure Declaration
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Indiana University School of Medicine (IUSM) and CME Outfitters, LLC, (CMEO) must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in activities sponsored by IUSM and CMEO are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Note: While it offers CME credits, this activity is not intended to provide extensive training or certification in the field.
Dr. McIntyre has disclosed that he receives grants/research support from Eli Lilly and Company, Janssen-Ortho, Inc., and Shire Pharmaceuticals, as well as Private Industries or Non-Profit Funds: Stanley Medical Research Institute, National Alliance for Research on Schizophrenia and Depression (NARSAD). He serves on the advisory boards of AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, France Foundation, GlaxoSmithKline, Janssen-Ortho, Inc., Solvay/Wyeth, Eli Lilly and Company, Organon, H. Lundbeck A/S, Biovail Pharmaceuticals, Inc., Pfizer Inc., Shire Pharmaceuticals, and Schering-Plough Corporation. He serves on the speakers bureaus of Janssen-Ortho, Inc., AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, H. Lundbeck A/S, Biovail Pharmaceuticals, Inc., Wyeth Pharmaceuticals, and Schering-Plough Corporation.
Dr. Citrome has disclosed that he recieves payments to institution for research from AstraZeneca Pharmaceuticals LP, Lilly USA, LLC, Pfizer Inc., and Janssen, L.P. He serves on the speakers bureaus of AstraZeneca Pharmaceuticals LP, Lilly USA, LLC, Merck & Co., Inc., and Pfizer Inc. He serves as a consultant to Lilly USA, LLC, GlaxoSmithKline, Janssen, L.P., Merck & Co., Inc., and Pfizer Inc.
Dr. Sachs has disclosed that he receives grant support from GlaxoSmithKline, National Institute of Mental Health, and Repligen Corporation. He serves as a consultant to, or on the advisory boards of, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cephalon, Inc., Concordant Rater Systems, Eli Lilly and Company, GlaxoSmithKline, Janssen, L.P., Merck & Co., Inc., Otsuka America Pharmaceutical, Inc., Pfizer Inc., Schering-Plough Corporation, Sepracor Inc., Repligen Corporation, Sanofi-aventis, and Wyeth Pharmaceuticals.
Dr. Anand has disclosed that he has received honoraria from Pfizer Inc. as a consultant, and has received research grants from Eli Lilly and Company and AstraZeneca Pharmaceuticals LP as an independent investigator.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Indiana University School of Medicine, CME Outfitters, LLC, the faculty, Bristol-Myers Squibb Company, Otsuka America Pharmaceutical, Inc., and Pfizer Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
TV-066-021710-99
